Ageing as a Risk Factor for Disease  by Niccoli, Teresa & Partridge, Linda
Current Biology 22, R741–R752, September 11, 2012 ª2012 Elsevier Ltd All rights reserved http://dx.doi.org/10.1016/j.cub.2012.07.024ReviewAgeing as a Risk Factor for DiseaseTeresa Niccoli1 and Linda Partridge1,2
Age is the main risk factor for the prevalent diseases
of developed countries: cancer, cardiovascular disease
and neurodegeneration. The ageing process is deleterious
for fitness, but can nonetheless evolve as a consequence
of the declining force of natural selection at later ages,
attributable to extrinsic hazards to survival: ageing can
then occur as a side-effect of accumulation of mutations
that lower fitness at later ages, or of natural selection in
favour of mutations that increase fitness of the young
but at the cost of a higher subsequent rate of ageing.
Once thought of as an inexorable, complex and lineage-
specific process of accumulation of damage, ageing has
turned out to be influenced by mechanisms that show
strong evolutionary conservation. Lowered activity of the
nutrient-sensing insulin/insulin-like growth factor/Target
of Rapamycin signalling network can extend healthy
lifespan in yeast, multicellular invertebrates, mice and,
possibly, humans. Mitochondrial activity can also pro-
mote ageing, while genome maintenance and autoph-
agy can protect against it. We discuss the relationship
between evolutionarily conserved mechanisms of ageing
and disease, and the associated scientific challenges
and opportunities.
Introduction
Better medical care and living conditions in developed coun-
tries have increased both health and life expectancy, from
around 50 years in the early 1900s to over 80 at the present
time. However, age is the main risk factor for major de-
bilitating and life-threatening conditions, including cancer,
cardiovascular disease and neurodegeneration (Figure 1),
all of which are therefore increasing in prevalence. Under-
standing exactly how ageing increases risk of disease is
needed to help to tackle this growing problem.
Not long ago, ageing was assumed to be an intractably
complex process, resulting from accumulation of multiple
formsof damageandpathology in different tissues as a result
of failure of cellular maintenance pathways. Evolutionary
analysis also tended to confirm the intractability of ageing
for experimental analysis or medical intervention. Natural
selection acts against ageing, because an organism that
does not agewould leavemore offspring. However, the force
of natural selectionweakenswith age [1–3] because extrinsic
hazards such as disease and accidents means that most
individuals do not survive to be old: deleterious mutations
with an advanced age of onset, such as those causing
Huntington’s disease (HD), can therefore accumulate [1,2],
and natural selection can favour mutants with beneficial
effects in youth but at the cost of a subsequently higher
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trait, and both suggest a complex genetic basis for
ageing [3,5].
Surprisingly, however, mutations in single genes were
found to extend healthy lifespan in the nematode worm Cae-
norhabditis elegans [6–8]. Subsequently, mutations in com-
ponents of the nutrient-sensing insulin/insulin-like growth
factor (IIS)/Target of Rapamycin (TOR) signalling network
proved to extend healthy lifespan in the budding yeast
Saccharomyces cerevisiae, C. elegans, the fruit fly
Drosophila and mice [9,10]. Recent genetic association
studies suggest that this network may also play a role in
human ageing [11–13], implying strong evolutionary conser-
vation. Drugs targeting nutrient-sensing networks, like rapa-
mycin andmetformin, can also extend lifespan (see Box 1 for
details). These are licensed for human use, raising the possi-
bility of modulating ageing in humans pharmacologically;
however, both have side effects, which will need to be mini-
mised when developing long-term treatment regimes to
improve health during ageing.
Importantly, interventions that prolong lifespan can
also decrease morbidity and improve health during
ageing [14,15]. For example, nutrient-sensing mutants in
C. elegans are resistant to tumours [16] and IIS mutant
mice are resistant to Alzheimer disease (AD) pathology
[15]. Rapamycin treatment of AD mouse models can also
improve pathology [17] and dietary restriction (DR), the
best-studied longevity-promoting intervention [14,18],
provides a broad spectrum of health benefits (see Box 2
for details). Interestingly, lifespan extension and improve-
ment in pathology don’t always correlate [15,19], suggesting
that amelioration of pathology may require particular modu-
lations of pathway activity, or alterations within specific cell
types.
As well as nutrient-sensing pathways, several other con-
served traits, including mitochondrial activity, DNA damage
response and telomeres, and autophagy are associated
with ageing, and also play a surprisingly prominent role in
disease development (Table 1). Deleterious mutations
affecting predominantly later ages may play a role in disease
aetiology. In addition, processes that are beneficial to the
young, for instance because they increase fecundity, may
contribute to later disease development, either because
the activities that they promote in the young generate
damage [20], or because the same activities that were bene-
ficial in youth are harmful to the old; for instance, pathways
that promote cell growth and proliferation potentially con-
tribute to cancer [21]. Components of ageing pathways
could therefore provide both novel, disease-relevant thera-
peutic targets, and also candidates for a broad-spectrum,
protective effect.
Several conserved mechanisms are implicated in age-
ing.Some, suchasnutrient-sensingpathwaysandmitochon-
dria, maintain metabolic and energy homeostasis; others,
such as DNA repair and autophagy, repair damage. We will
focus on a few key examples and consider their role in aeti-
ology of disease, exemplified by cardiovascular disease,
neurodegeneration and cancer (Box 3, Table 2). Some rela-
tionships have been examined in great detail, such as DNA
repair and cancer, while others have barely been touched
on, like autophagy and cardiovascular disease.
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Figure 1. Disease or total death rates for the most common diseases of old age.
(A) Cardiovascular disease incidence in England in 2006 (source: British Heart Foundation ‘Coronary heart disease statistics’ 2010). (B) Dementia
prevalence in EU countries in 2006 (source: Alzheimer Europe, 2009). (C) Age-specific mortality rates per 100,000 population, UK (source: Cancer
Research UK).
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The IIS [22], TOR and AMP kinase (AMPK) signalling cas-
cades sense the nutritional state of the organism and relay
this information to cells, which modulate their metabolism
accordingly (Figure 2). Nutrient-sensing pathways promote
growth during development and contribute to fecundity
[23]; however, their down-regulation can increase lifespan
in yeast,C. elegans, Drosophila andmice [5,9,10,15]. Genetic
variants in a key IIS transcriptional effector, FOXO3A, are
also consistently associated with human longevity [12].
Candidate mediators of this effect are reduced cell growth
and proliferation at later ages, altered mitochondrial activity
and increased cellular detoxification and/or autophagy.
Autophagy is regulated both by AMPK and TOR, and is
required for lifespan-extension by rapamycin in flies, worms
and yeast [24,25]. Mitochondrial homeostasis and respira-
tion are enhanced by activation of AMPK [26] and inhibition
of TOR [27]. Detox pathway components are up-regulated
in IIS mutants in flies, worms and mice, and can extend life-
span in worms and flies [5]. However, the relative contribu-
tion of each component is unknown. The mechanisms by
which the network contributes to ageing-related disease
may be the same as those that cause ageing, or may be to
some extent disease-specific.
Cardiovascular
IIS/TOR signalling plays a systemic role in cardiovascular
disease, by regulating metabolism, and a cell-autonomous
one in cardiac function itself. Insulin regulates sugar and
fat metabolism, and facilitates uptake of glucose by
insulin-responsive tissues to be stored as fat. The nutritional
conditions prevailing in nature and during the early evolution
of humans would have led to strong selection for the ability
to store calories during periods of food abundance for
use during food scarcity. However, the ready availability of
food for many modern humans combined with reduced
energy expenditure on activities, including exercise, immune
response and thermoregulation, can cause excessive food
intake and insulin secretion and hence accumulation of
visceral fat and insulin resistance, major risk factors for
cardiovascular disease [28,29]. Inhibition of IIS in the fat
body of a Drosophilamodel of high-fat-diet-induced obesityprevents lipid accumulation and protects the heart from
pathology [30], underscoring the role of IIS in obesity and
disease development.
Obesity triggers insulin resistance through several mecha-
nisms. Adipocytes secrete free fatty acids and adipokines,
which can inhibit IIS in peripheral tissues, leading to insulin
resistance, hyperglycaemia (because sugar is no longer
cleared from the blood) and type II diabetes [29]. Insulin
resistance and hyperglycaemia can contribute directly to
the formation and progression of atherosclerotic lesions
(for details see [31]), a major cause of cardiovascular disease
(Box 3). Accordingly, individuals who maintain high insulin
sensitivity are less at risk of cardiovascular disease [28].
Strikingly, centenarians maintain high insulin sensitivity
[28], whereas genetic variants associated with decreased
insulin signalling are associated with insulin resistance and
diabetes [31], suggesting systemic IIS pathway activation it-
self confers protection from cardiovascular disease in the
absence of obesity.
TOR also links obesity and heart disease, through several
mechanisms [29]. IIS can activate mTORC1, which, via
S6K1, phosphorylates and down-regulates Insulin Receptor
Substrate 1 (IRS1). Mice null for S6K1 lack this negative feed-
back and do not develop diet-induced insulin resistance [29].
In a Drosophila model of diet-induced cardiac dysfunction,
inhibition of TOR signalling, especially in the heart and fat
body, rescues cardiac pathology and increases insulin
sensitivity [27,32].
Nutrient-sensing pathways also act directly on the heart to
influence its function. The heart is insulin-responsive and can
develop obesity-induced insulin resistance [33], associated
with cardiac remodelling and systolic dysfunction [29].
Both IIS and AMPK activation improve outcome following
infarction [33,34–36]. IIS promotes vascular reperfusion
and increases glucose availability [33], whereas AMPK stim-
ulates glycolysis and maintains energy homeostasis when
oxygen supply decreases [35,36], thus protecting the heart
from ischaemic damage. However, long-term IIS activation
can lead to pathological hypertrophy and heart failure [37]
and in Drosophila reducing IIS signalling systemically or
specifically in the heart rescues age-related cardiac func-
tional decline [38].
Box 1
Drugs extending lifespan.
Rapamycin
Rapamycin inhibits mTOR, and can increase lifespan in worms, flies and mice [49,118]. By inhibiting mTOR, rapamycin induces autophagy,
which is required for lifespan extension in flies, worms and yeast [104]. Other mechanisms of action include inhibition of S6 kinase, essential
for its lifespan effect in flies [25], and inhibition of growth and proliferation [45].
Metformin
Metformin is an AMPK activator that can extend lifespan in mice and C. elegans [119]. Multiple mechanisms could be at work. Metformin
reduces hyperglycaemia in several ways and boosts insulin sensitivity, which has been associated with mammalian, including human,
longevity [28]. Formetformin to extend lifespan inC. elegans, AMPK activity and SKN-1/Nrf2 (nuclear factor, erythroid derived 2), an oxidative
stress-responsive transcription factor that has itself been linked to ageing [119], are both required. Metformin also inhibits mTOR and boosts
mitochondrial function, which could also contribute to its effect on lifespan [120].
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expression of TOR protects against dysfunction following
overload [29] and loss of TOR is detrimental. TOR also
induces cardiac hypertrophy, which is important in young
fit adults in order to increase cardiac output in response to
exercise, but in later life TOR-mediated pathological cardiac
hypertrophy can lead to heart failure, which can be amelio-
rated by rapamycin [29], suggesting that quantitative and
context-specific modulation of TOR is important.
Nutrient-sensing pathways therefore act in multiple,
sometimes opposing, manners to modulate cardiovascular
disease development and their effects are context-specific.
Neurodegeneration
Nutrient-sensing pathways act indirectly via cardiovascular
disease to affect AD because the risk of AD is related to
cardiovascular disease risk profile, and AD may indeed
have a strong vascular component [39]. IIS signalling also
plays a direct role in neuronal development, maintenance
and pathology [40], albeit not a simple one. Reduced IIS
specifically in neurons extends lifespan in C. elegans,
Drosophila and mice [41], and also ameliorates proteotoxic-
ity and neurodegenerative disease in animal models [42].
However, insulin can also be neuroprotective: insulin resis-
tance impairs memory, is a risk factor for AD and exacer-
bates Aß deposition in mice [43], and AD patients show
reduced insulin signalling, associated with increased tauBox 2
Dietary restriction.
Dietary restriction (DR), the best-studied longevity-promoting interven
primates [14]. It also provides a broad spectrum of health benefits. DR
including cancer, diabetes, atherosclerosis, cardiomyopathy, respirato
extend to primates: DR rhesusmonkeys have reduced incidence of diab
humans on a DR diet for a limited period of time show a decrease in risk
in glucocorticoid function and increased insulin sensitivity [14]. However
it increases lifespan, it does not ameliorate neuronal dysfunction in aDro
and bone function [121]. Moreover, DR has a detrimental effect on som
infection [14] and impaired wound healing that can be restored upon fu
might have drawbacks.phosphorylation, a hallmark of AD [43]. Knock-out of the
Irs2 gene in mice also leads to increased phosphorylation
of Tau but, surprisingly, it ameliorates Aß pathology [15],
suggesting that insulin signalling might have opposing
effects on different aspects of AD aetiology. Acute insulin
administration can promote memory in rodents, humans
[43] and, possibly, in patients with early AD [44], although
the effects on disease development are unknown. Hence,
IIS can have both positive and negative effects on neuronal
decline, possibly depending on the level or mechanism of
pathway alteration.
TOR also plays a complex role in neurodegenerative
disease. TOR signalling is enhanced in AD neurons, where
it may promote tau-mediated neurodegeneration, but it is
reduced in cultured cells exposed to Aß, while the TOR inhib-
itor RTP801 is elevated in the brains of Parkinson’s disease
(PD) patients [45]. Inhibition of TOR with rapamycin amelio-
rates toxicity in fly and mouse models of PD, HD, AD and
amyotrophic lateral sclerosis (ALS) [45], mostly by activating
autophagy, but also by decreasing translation and inhibit-
ing apoptosis [45]. Pharmacological inhibition of TOR is
hence a possible therapeutic avenue for neurodegenerative
disorders.
Cancer
Cancer, unlike cardiovascular disease and neurodegenera-
tion, is characterised by unwanted cell replication rathertion [18], can increase lifespan in diverse species from yeast to
mice are protected against multiple age-associated diseases,
ry diseases and neurodegeneration [14]. These health benefits of DR
etes, cancer, cardiovascular disease, and brain atrophy [14]. Indeed,
factors associated with coronary heart disease [14], an improvement
, DRdoes not protect against all disease-related pathology: although
sophilamodel of AD [19] and in humans DRdoes not improvemuscle
e aspects of immunity; DR mice can show increased susceptibility to
ll feeding [14], indicating that its practice in a real-life environment
Table 1. Role of ageing pathways in disease.
Pathway Effects on cardiovascular disease Effects on neurodegeneration Effects on cancer
IIS/TOR
AMPK
Insulin resistance is associated with
diabetes and cardiac dysfunction.
Insulin, TOR and AMPK have
cardio-protective role. TOR and IIS
downregulation can sometimes
also be protective
Increased signalling might be
protective; however, long lived IIS
mutants with reduced signalling
improve pathology
Negative regulators of IIS and TOR
signalling are tumour suppressors
Mitochondrial function Defective mitochondria lead
to cardiomyocyte apoptosis,
and cell loss in the heart
Impairment in function and
morphology is associated and
appears to promote pathology,
especially in PD
mtDNA mutations are oncogenic.
Mitochondria via ROS production
can drive malignancy progression
DNA damage response
(DDR) and telomeres
High DNA damage and telomere
shortening increase endothelial
senescence leading to atherosclerosis;
however, telomerase
is active in later stages of
atherosclerosis. Could also
contribute to cell loss in the heart
Attempted re-entry into the cell
cycle following DNA damage can
lead to neuronal cell death in
neurodegenerative diseases
Telomere role uncertain
Defects in DDR allow cancer cells
to accumulate mutations and
grow uncontrollably
Telomere shortening leading to
replicative senescence is one of the
main breaks on tumour progression
Autophagy Defects in autophagy lead to
cardiomyopathy and cardiac
hypertrophy. Defects in autophagy
also protective for cardiac
remodelling following overload
Defects in autophagy lead to
accumulation of toxic protein
aggregates and defective
mitochondria, contributing
to pathology
Autophagy is protective to early
stages of tumour growth; however,
it helps cancer cells spread in
later stages
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R744than cell death (Box 3). Nutrient-sensing pathways generally
stimulate growth in response to nutrient availability. Accord-
ingly, hyperinsulinaemia stimulates cell division and can
induce cancer [46] and positive regulators of IIS signalling
are usually oncogenic whereas negative regulators are
tumour suppressors [47]. Mutations extending lifespan in
C. elegans, Drosophila and mice can hence also be tumour
suppressors [48]. Drugs targeting nutrient-sensing path-
ways, such as rapamycin derivatives and metformin, are
promising anti-cancer treatments in humans. Rapamycin is
already in clinical use as a cancer chemotherapeutic [49]
and epidemiological analysis has implicated metformin in
protection against cancer [50]. Whether down-regulating
IIS/TOR signalling affects tumour progression by inhibiting
growth or by other mechanisms remains to be clarified. For
example, it may boost immunity [15,51], because cancer de-
velopment is promoted in immunodeficient mouse models
[52]; however, rapamycin is an immunosuppressant, so this
is unlikely to be its mechanism of action.
Cancer cells switch from oxidative phosphorylation, active
in post-mitotic, differentiated cells, to aerobic glycolysis,
usually active in highly proliferating cells, thus diverting
glucose into production of biomass to support the high level
of cellular proliferation [53]. Glycolysis also allows cells to
proliferate in hypoxic conditions, common in tumours [54].
This switch is regulated by components of nutrient signalling
pathways, such as phosphoinositide 3-kinase (PI3K)/Akt
[53], TOR [55] and oncogenic Ras [54]. Therefore, inhibiting
these pathways could also inhibit this metabolic switch
and reduce tumour cell proliferation.
Mitochondria
Mitochondria produce most of the cell’s energy, in the
form of ATP, through respiration. As a by-product, reactive
oxygen species (ROS) are generated. Until recently, ROS
were considered a leading cause of ageing. However, direct
experimental evidence for this hypothesis is lacking [56,57],
because reduced activity of antioxidant enzymes can in-
crease susceptibility to oxidative stress without affectinglifespan [58], while increased protection by over-expression
of antioxidant enzymes does not generally increase lifespan
[58,59], or does so by means other than reduced production
of ROS [60].
Mitochondria, however, probably do play an important role
in ageing. Transcription of genes encoding mitochondrial
proteins declines with age [42], and impaired mitochondrial
fission leads to disorganized mitochondrial morphology
[61]. Whether these changes are purely a result of age-
specific genetic effects or are a consequence of events
beneficial earlier in life remains to be seen. Moderately
reduced mitochondrial activity can increase lifespan in
yeast, worms, flies and mice [10], although the exact mech-
anisms at work await discovery.
The role ofmitochondria in diseasedevelopment is notwell
explored, with notable exceptions such as PD. However, evi-
dence is emerging that they have an important role in cardio-
vascular disease and as a driver for cancer progression.
Cardiovascular
Cardiomyocytes contract constantly, and hence require
highly efficient mitochondria to meet their energy demands.
Dysfunctional mitochondria accumulate in ageing cardio-
myocytes [62], leading to reduced energy production and
impaired contractility. Excessive accumulation of defective
mitochondria triggers apoptosis, and the resulting cell loss
can contribute to heart failure [63]. ROS production from
mitochondria can stimulate cellular events, leading to patho-
logical myocardial remodelling and consequent heart failure
[64]. A mouse model with increased mitochondrial (mt)DNA
mutation rate shows traits characteristic of premature
ageing and an enlarged heart [65], suggesting that normal
mitochondrial function is important for heart function.
Neurodegeneration
Neurons also have a high oxygen consumption and rely
on efficient mitochondria. Indeed, genetic disorders of mito-
chondria predominantly impair neuronal and muscle func-
tion, and occur in many neurodegenerative diseases [66].
Box 3
Diseases of old age.
Cardiovascular disease
Cardiovascular disorders are the leading cause of death in the western world [122]. The term encompasses any disease affecting the heart or
the circulatory system, the two most prominent forms being coronary heart disease and stroke. The main common cause of cardiovascular
disease is atherosclerosis, caused by the localised accumulation of cholesterol within the walls of arteries, leading to the formation of hard
plaques and the narrowing of the arterial lumen and, occasionally, the break-off of a clot. Both can lead to a blockage, cutting-off vital
oxygen supply and causing downstream tissue death. In the heart this leads to an acute myocardial infarction (AMI) and in the brain to
a stroke.
The other main risk factors for cardiovascular disease are obesity, HDL/LDL ratio, type II diabetes, high blood pressure [62] and, mostly, age
(Figure 1). In fact, older people are not only more likely to develop AMI, but also more likely to die from it [62]. This is possibly because even
healthy heart function declines with age due to cardiomyocyte loss, decrease in contractility, decrease in stress resistance, cardiac
hypertrophy and fibrosis [35].
Neurodegeneration
Neurodegenerative diseases are characterised by the progressive death of neurons and loss of brain structures. There are a number of these
disorders, with AD and PD being the most common. Although these conditions can affect different parts of the brain and present with
different symptoms (Table 2), age is the main common risk factor. Also in common is the abnormal deposition and mis-localisation of
insoluble protein aggregates, associated with progressive, age-related decline in neuronal function.
Exactly how age acts as the chief risk factor for these diseases is not clear. Insoluble, toxic proteins may accumulate with time, and older
neuronsmay bemore vulnerable to toxic effects. Abnormalities in protein turnover and processingmight alsomake older neurons less able to
degrade toxic proteins.
Cancer
Unlike cardiovascular and neurodegenerative diseases, which are characterized by cellular senescence, apoptosis and decreased mitosis,
cancer is characterized by uncontrolled cellular proliferation, where cells become unresponsive to the usual check-points, leading to tumour
growth and metastasis.
Age, a family history of disease and an unhealthy lifestyle increase the risk of developing cancer. However, environmental exposure to
specific factors, such as tobacco, sunlight, viruses and certain hormones, seems to play amuch greater role, which varieswith different types
of cancer: tobacco for lung cancer, sunlight for melanoma and papillomavirus for cervical cancer, to give some examples.
Why older people aremore susceptible to cancer is not totally understood: cellsmight need time to accumulate enoughmutations to become
cancerous or older individuals might be more susceptible to oncogenic mutations [123].
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R745Several mutations causing autosomal recessive PD are
directly or indirectly involved in mitochondrial metabolism
[67]. In particular, PINK1 and Parkin affect mitochondrial
morphology and turnover in Drosophila and mouse models
[68]. In PD brains, the activity of the mitochondrial electron
transport chain (ETC) complex I is often reduced, and
exposure to an ETC complex I inhibitor causes PD-like
symptoms in both animals and humans [67]. Mitochondria
may thus be important in the aetiology of sporadic PD,
although the precise mechanisms are an area of current
research focus.
In AD, Aß accumulation in mitochondria is associated with
reduced activity of ETC complexes III and IV and of COX [67].
Human AD brains and animal and cellular models of AD
display defects in mitochondrial transport and morpholo-
gy, possibly mediated by Drp1, a dynamin-related protein
important for mitochondrial fission [67]. Whether these mito-
chondrial defects are a cause or consequence of AD aeti-
ology remains controversial.
Impairment of mitochondrial function in AD and PD could
be caused by mtDNA ROS damage; in both AD and PD,
deletions, mutations and fragmentation of mtDNA are ob-
served [67]. This could trigger apoptosis, thus contributing
to neurodegeneration [66]. The mitochondria-targeted anti-
oxidant MitoQ prevents loss of spatial memory and early
neuropathology in a transgenic AD mouse model [69],indicating a possible causal link between ROS-induced
mtDNA damage and neurodegeneration.
Mitochondrial defects also occur in HD, and modulat-
ing mitochondrial function can ameliorate the pathological
phenotypes of fly [70], and mouse [71] models, suggest-
ing that targeting mitochondrial function could be a viable
therapeutic approach, at least in some neurodegenerative
disorders.
Cancer
In cancer cells, mtDNA can be highlymutated, and numerous
polymorphisms and mtDNA mutations have been linked to
increased cancer susceptibility [72], suggesting that mtDNA
alterations, like nuclear genomic alterations, play an impor-
tant role in cancer development.
When cancerous cells up-regulate aerobic glycolysis,
mitochondrial activity is reduced. For example, the catalytic
subunit of mitochondrial ATP synthase is down-regulated
in human carcinomas [73]. The shift to glycolysis also makes
the mitochondria more stable and less able to activate
apoptosis, thus helping cancer cells to proliferate [73].
Recently, mitochondria have also emerged as a driver of
malignant transformation, through ROS production. In early
tumours, as mitochondrial activity is impaired, ROS pro-
duction increases, leading to further mtDNA damage, and
decreased mitochondrial function. This vicious circle of
Table 2. Characteristics of neurodegenerative disorders.
Disease Initial brain area affected Presentation Histological hallmarks Genetic factors
Alzheimer’s disease Entorhinal cortex,
spreading to temporal lobe
and frontal cortex
Memory loss and
behavioural disturbances
Extracellular plaques composed
of Aß protein and intracellular
neurofibrillary tangles composed
of Tau protein
APP, PS1 PS2, ApoE4,
PICALM, BIN1, PICALM,
CLU, CR1
Parkinson’s disease Dopaminergic neurons
of the substantia nigra
Resting tremor, postural
instability, gait disturbances,
bradykinesia and rigidity
Cytoplasmic inclusion called
Lewy bodies containing
aggregated alpha synuclein protein
a-synuclein, LRRK2,
PINK1, parkin and DJ-1
Huntington’s disease GABAergic neurons in
striatum and cortex
Chorea, psychiatric
disturbances and
cognitive impairment
Mutant Htt protein aggregates Htt
Amyotrophic lateral
sclerosis
Lower motor neurons in
the spinal cord and in the
brain stem; corticospinal
upper motor neurons in
the precentral gyrus; and,
frequently, prefrontal
motor neurons
Progressive muscle
weakness, muscular
atrophy, spasticity
and eventual paralysis
Cytoplasmic aggregates of SOD1,
FUS or TDP-43
SOD1, ALS2, FUS/TLS,
ALS10, TDP-43
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eventually leads to the accumulation of enough oncogenic
mutations to allow the tumour to metastasize [54]. Transfer-
ring mtDNA from a highly metastatic cell line can make
a poorly metastatic cell line highly metastatic, and inhibition
of ROS blocks this metastatic potential [74], implicating it in
driving cancer progression. Defects in mitochondrial func-
tion therefore not only impair tissue function (for example,
in neurons and cardiomyocytes) but also, through ROS
production, can act as a driver of disease development.
Pathways involved inmetabolism and energy homeostasis
can clearly have substantial effects on disease develop-
ment; however, the relationship is not a straightforward
one, where interventions that increase lifespan improve
pathology across the board. On the contrary, a complex
picture emerges, where the activity of these pathways has
to be modified in particular ways, to particular extents and
in specific tissues to confer protection against disease.
DNA Damage Response Pathway and Telomeres
Both environmental factors, such as UV irradiation and the
cell’s own metabolic processes (generating ROS) can lead
to DNA damage, which tends to accumulate with time
[75]. The DNA damage response (DDR) pathway plays a
crucial role in maintaining the integrity of an organism’s
DNA, by monitoring and repairing any damage and, if the
damage is too extensive, by triggering cellular senescence
and apoptosis.
The integrity of chromosome ends is ensured by specific
structures called telomeres, replicated by the telomerase
complex. In adult cells telomerase is only partially active,
and as the organism ages and cells divide, telomeres
shorten. Once telomeres become critically short, the DNA
damage checkpoint is activated, triggering replicative
senescence [76]. This system limits the number of times
a cell can divide and is one of the main brakes on tumour
development. Mutations in DDR components, such as p53
or Rb (retinoblastoma), lead to cancers in early life [77]. In
later life, however, telomere shortening and accumulation
of senescent cells may contribute to ageing; an example of
ageing occurring as a result of an activity that helps to
prevent cancer at younger ages. Telomere shortening
reduces the regenerative potential of stem cells [76] andclearance of senescent cells in a mouse model of premature
ageing delays ageing-associated pathologies [78]. More-
over, some p53 alleles that confer cancer resistance induce
early ageing in both humans and mice [79], suggesting that
the earlier cancer-resistance function does indeed, as
a side effect, induce ageing.
Defects in the DNA repair and telomerase pathway com-
ponents in humans and mice can result in premature ageing
[80], underscoring their importance in early life. Whether this
equates to a causal role in ageing is more controversial [81].
Manipulation of DNA repair and telomere pathways can
extend lifespan under certain conditions. Polymorphisms in
telomerase reverse transcriptase (hTERT) [12] have been
associated with longevity in humans, while increased telo-
merase activity can increase lifespan in cancer-resistant
mice [15]. However, mice have much longer telomeres than
humans, and any connection between telomere length and
rate of ageing across species is highly complex and does
not suggest any simple causal relationship [82].
Over-expression of p53, a powerful tumour suppressor
involved in DNA repair, can extend lifespan in Drosophila
and mice. However, a reduction of p53 activity is also asso-
ciated with lifespan extension in C. elegans, Drosophila and
humans [83]. Moreover, it is unclear whether p53’s role in
longevity is due to its interaction with the IIS and TOR
pathways [83], or its roles in cellular senescence [75] or
DNA repair [83]. Given the varied evidence, more work is
needed to clarify the importance of genomic maintenance
in ageing. Better established is its role in cancer, and recent
evidence points to a role in cardiovascular disease and
neurodegeneration (Figure 3).
Cardiovascular
Increased DNA damage and decreased telomere length
are associated with atherosclerosis, coronary artery disease
and heart failure [84,85]. The high levels of DNA damage and
shortened telomeres in the vascular endothelium are thought
to promote cellular senescence, which feeds the inflamma-
tory cycle, leading to plaque deposition [85,86]. The internal
mammary artery, which is protected from atherosclerosis,
has longer telomeres than other arteries [87] and increasing
telomerase activity can protect from endothelial senescence
[87], whereas reducing DDR by mutation of the ataxia
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Figure 2. Nutrient-sensing pathways.
Illustration of nutrient-sensing pathways’ re-
sponses to nutritional signals and how they
interact with each other. Dotted arrows repre-
sent negative feedback interactions between
the pathways. Upon insulin/IGF binding,
insulin-like receptors signal via the Insulin
Receptor Substrate (IRS) to Akt to inhibit
FOXO and stimulate the glucose transporter
(GluT) to allow glucose import. Amino acids
stimulate TOR via TSC1/TSC2 inhibition to
down-regulate autophagy and promote trans-
lation via S6K and 4EBP. ATP levels modulate
AMPK, which can promote autophagy and
also interacts both with the IIS and TOR path-
ways. In a number of organisms there are
multiple paralogue copies of insulin-like
receptors, IRS, FOXO and GluT, but for
simplicity only one is depicted.
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R747telangiectasia mutated (ATM) protein
worsens the vascular phenotype of
a mouse model of atherosclerosis [84],
suggesting that DDR and telomeres
play a protective role in atherosclerosis.
However, late atherosclerotic lesions
induce proliferation of vascular smooth
muscle cells, which requires telome-
rase activity, and mice with shortened
telomeres are protected from aortic
atherosclerosis [87], suggesting a
complex relationship.
DNA damage and short telomeres in
ageing cardiomyocytes may lead to
cell loss by increasing cellular senes-
cence and apoptosis, and limiting the
proliferative potential of cardiac progenitor cells, thus
contributing to heart failure [62,87]. Mutations in DDR genes,
including ATM and BRAP2, increase the risk of developing
ischaemic heart disease in humans [84]. In mice, short telo-
meres halve cardiomyocyte numbers and increase heart
dysfunction, whereas increased telomerase activity reduces
apoptosis and improves function following ischemic injury
[87], indicating a protective role for telomeres and DDR in
cardiac function.
Neurodegeneration
Post-mitotic neurons are both metabolically active and long-
lived, and over the course of a lifetime gradually accumulate
DNA damage. This initially compromises the expression of
subsets of genes important for neuronal function [88] and
eventually triggers cell cycle re-entry, which in neurons
leads to apoptosis and neurodegeneration [11]. DNA
damage and markers of cell cycle re-entry accumulate in
brains of patients with AD or PD and in disease models
[11,89] and inhibiting cell cycle re-entry blocks apoptosis
in these models [90]. Cdk5, p53 and ATM have all been
implicated in cell cycle re-entry in both AD and PD, and
blocking Cdk5 activation inhibits tau hyperphosphorylation,
cell-cycle re-entry, synaptic loss and neuronal death trig-
gered by Aß in mice [90]. Recently, two DNA damage
biomarkers, chitinase (chitotriosidase activity) and stathmin
protein, were found to be significantly increased in AD and
non-AD dementia, although any causal link between thesebiomarkers, DNA damage and AD development is yet to
be demonstrated [91].
Telomerase expression is high in neuronal stem cells and
is important for brain development [92]; it decreases in differ-
entiated neurons, but can be reactivated in response to
stress, where it may play a protective role, because inhibiting
telomerase increases neurons’ susceptibility to apoptosis
[93]. The role of telomeres in neurodegeneration is much
less clear. Telomere shortening seems to play no role in
PD development [94] and, surprisingly, seems to be protec-
tive in AD [95]. Further work will be required to clarify
mechanisms.
Cancer
The main hallmark of cancer is genomic instability leading
to uncontrolled cell proliferation, and most cancer risk
factors cause DNA damage. Many DDR components were
first identified as tumour suppressors and patients harbour-
ing DDR mutants are highly susceptible to cancer [96]. In
cancer cells, DDR pathway components, such as ATM and
BRCA1, have to be impaired for a tumour to develop [97],
allowing cells to proliferate regardless of their damaged
DNA, and without repairing it, which leads to further DNA
damage and, eventually, to a highly proliferating and muta-
genized cellular population that can escape its local environ-
ment and metastasise.
The induction of senescence in response to DNA damage
is mediated by well known tumour suppressors such as p53
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Figure 3. DNA repair in disease development.
Diagram of the contribution of DNA damage
repair to the development of disease. (A) By
inducing senescence and apoptosis in cardio-
myocytes, DNA damage repair contributes to
heart disease. (B) Triggering cell cycle re-
entry contributes to neurodegeneration; (C)
but when working efficiently blocks cancer
development.
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R748or Rb1 [98] and limits the proliferative potential of damaged
cells, providing the main protection an organism has against
cancer. Accordingly, an activated DDR, inducing cellular
senescence, has been observed in early, benign lesions
with accumulated DNA damage [99,100]. The importance
of p53 has been underscored by two studies showing that
re-activation of p53 in tumours leads to their clearance;
however, this was at least partly due to induction of an
innate immune response that targeted the tumour cells
in vivo [101,102].
Limiting proliferative potential of useful cells (such as stem
cells) could, however, contribute to ageing phenotypes. But
p53 can also protect against both cancer and ageing; mice
with increased expression of p53 and Arf were resistant to
both [103], suggesting that cancer resistance and longevity
are not mutually exclusive.
Another mechanism that helps to prevent cancer devel-
opment is replicative senescence induced by telomere
shortening. To overcome this barrier cancer cells either
activate telomerase or have found a way to replicate their
telomeres in the absence of telomerase [98]. Confirming
the role of telomeres, mice with short telomeres are resis-
tant to tumours whereas transgenic mice with increased
TERT (the catalytic subunit of telomerase) activity are
susceptible to cancers [76]. However, activation of telome-
rase in cancer-resistant mice does increase lifespan [76],
again demonstrating that cancer resistance and longevity
can co-exist.
DDR and replicative senescence due to telomere short-
ening therefore provide an efficient barrier to cancer devel-
opment throughout life, and would probably have come
under selective pressure for this role but, in later life, might
also induce cell loss in post-mitotic tissues such as the heartand brain, contributing to cardiovas-
cular disease, neurodegeneration and
ageing.
Autophagy
Autophagy allows digestion of cyto-
plasmic material and organelles by
lysosomes [104]. This contributes to
cellular maintenance by eliminating
and recycling damaged components,
and provides biofuel for the cell. Its
role in aging has gained prominence
in recent years. Autophagy plays a
crucial role in youth, since both ele-
vation of and defects in autophagic
activity can impair fitness [104]. Ex-
pression of the proteins required for
autophagy declines in ageing tissues
and in age-related disorders [104],
and correcting this deficiency inmouseliver can ameliorate age-related phenotypes [104]. The exact
reasons for the age-related decline in expression of auto-
phagy genes are unknown. Such defects in gene expression
are a more general feature of ageing [105], but why the
reduced intensity of natural selection should lead to this
outcome is not clear.
Many lifespan-extending interventions require autophagy
[104]. For example, rapamycin cannot extend lifespan if
autophagy is inhibited [104]. Moreover, in Drosophila,
brain-targeted overexpression of Atg8, a component of the
autophagy pathway, is sufficient to extend lifespan [104].
Autophagy could promote longevity by a number of
mechanisms. It helps to clear toxic proteins and defective
mitochondria, it suppresses oncogenic transformation and
could help maintain stem cells, boost immune function and
possibly regulate insulin homeostasis [104]. Any of these
downstream effectors could mediate its lifespan effect, and
the exact mechanisms await further clarification.
Its role in disease development is also gaining increasing
attention.
Cardiovascular
Autophagy plays an important role in cellular maintenance in
the myocardium. During ageing, autophagic flux is slowed,
leading to accumulation of damaged and toxic organelles
and proteins, which can lead to cardiac dysfunction and
heart failure [106]. Patients with mutations in lysosomal
associated membrane protein 2 (LAMP2), which is required
for lysosome-autophagosome fusion, have defects in auto-
phagy leading to severe cardiomyopathy [106], strongly
implicating autophagy in the maintenance of a healthy heart.
Experimental models confirm the importance of autophagy,
which is induced in response to cardiac injury in a number
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Figure 4. Current therapies target individual
diseases in isolation; therapies targeted to
the ageing process itself aim to cover many
diseases simultaneously.
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R749of animal models [107]. Decreasing
autophagy — for example, by de-
creasing the level of autophagy protein
5 (atg5) — leads to hypertrophy and
heart failure in a mouse model [106].
However, decreasing Beclin-1 function
reduces autophagy induction and de-
creases maladaptive cardiac remodel-
ling following overload [106]. This
suggests that whereas autophagy is
required for myocardial homeostasis, excessive induction
following a cardiac insult might be detrimental.
Neurodegeneration
Because autophagy can remove protein aggregates, which
are associatedwithmost neurodegenerative diseases (Table
2), it is perhaps unsurprising that it plays a protective role
[104]. In AD, PD and HD brains autophagic and lysosomal
vesicles accumulate, suggesting a blockage in the auto-
phagy process [108]. The toxic proteins associated with
neurodegeneration might directly inhibit autophagy. For
instance, humanAß inhibits autophagy in aDrosophilamodel
[109], pathogenic alpha-synuclein can inhibit chaperone-
mediated autophagy, and mutation of Htt perturbs ER func-
tion leading to an increase in autophagosomes [108]. Genetic
or pharmacological enhancement of autophagy can amelio-
rate phenotypes in a number of neurodegenerative disease
models in Drosophila [42] and mice [110], whereas inhibition
of autophagy by hyperactivation of TOR [111] or mutants in
autophagy itself promote protein aggregation and neurode-
generation in various model organisms [104,112].
Autophagy also removes defective mitochondria, espe-
cially important in post-mitotic cells such as neurons [104]
and PD-associated PINK1 and Parkin selectively target
defective mitochondria to autophagic degradation, with
defects in these genes resulting in accumulation of defective
mitochondria, leading to PD [108,113]. Autophagy’s protec-
tive role in neurodegeneration could therefore also be due
to its role in mitochondrial clearance.
Cancer
Oncogenes tend to inhibit and tumour suppressors
activate autophagy, suggesting that autophagy needs to
be down-regulated for cancer proliferation [98,114]. How-
ever, abrogation of autophagy in mouse models (by atg5
or atg7 deletions) leads to an increase only in benign
tumours, suggesting that total lack of autophagy promotes
the initial stages of cancer development but prevents tumour
metastasis [114].
Partial impairment of autophagy, on the other hand,
promotes malignancy: human breast and ovarian cancers
often show loss of one copy of the BECN1 gene, which
only partly decreases autophagy, and mice heterozygous
for BECN1 show an increase in benign and malignant
tumours [114]. This could be because once a tumour is es-
tablished, autophagy becomes re-activated and promotes
cancer survival [114]. ROS, hypoxia and nutrient deprivation,all experienced by cancer cells, stimulate autophagy. Also,
the initial conditions promoting mutagenesis and allowing
cell transformation, such as DNA instability and ROS, would
hinder rapid growth. Autophagy re-activation helps reduce
damaged organelles and proteins allowing the tumour cells
to thrive while providing amino acids and fatty acids to fuel
the growth and themetabolic reactions of these highly prolif-
erating cells. A number of cancers, such as Ras-positive
ones, show a high level of basal autophagy and its down-
regulation impairs cancer cell metabolism and tumour
growth [114]. Chemotherapy drug combinations that include
autophagy inhibitors have shown promise in pre-clinical
trials and animal models [114,115]. Further studies will be
needed to establish the true efficacy of this approach in
cancer therapy and whether it is indeed attributable to
altered autophagy, rather than some other, as yet unknown,
function.
Conclusions
With age, the disease burden increases. Interestingly, the
same pathways that modulate longevity affect the develop-
ment of multiple, age-related pathologies. Ageing as a
disease risk factor can be thought of as the accrued effect
of a finite number of evolutionarily conserved pathways.
These pathways either have been selected for a specific
beneficial function in earlier life, for instance DNA repair,
and, as a side effect, actively contribute to the ageing
process, or come under weakening evolutionary pressure
later in life and therefore accumulate mutations with delete-
rious effects in aged organisms. Interestingly, interventions
that extend lifespan in model systems often appear to lead
to a broad spectrum improvement in health [9,15]. However,
the effect on specific disease models often appears more
complex. Conflicting reports in the literature might suggest
that the efficacy of a particular intervention is specific to
the experimental approach used. The exact molecular
component targeted may be important. For example, insulin
or IGF1 receptors, usually assumed to be involved in IIS,
have a pro-apoptotic function independent of IIS [116], sug-
gesting that some outcomes may be mediated by another,
unidentified, role of the particular protein targeted. With
these considerations in mind, however, the consistent asso-
ciation between processes involved in ageing and ageing-
related disease aetiology suggests that it should be possible
to modulate these processes to improve the cellular and
systemic environment of older individuals and provide
a broad-spectrum health improvement (Figure 4).
Table 3. Lifespan- and disease-specific effects of rapamycin and metformin.
Rapamycin Metformin
Lifespan Extends lifespan in mice, worms and flies Extends lifespan in mice and worms
Cardiovascular Decreases pathological cardiac hypertrophy
Reduces restenosis following stent procedure
Reduces type II diabetes and its associated
complications
Neurodegeneration Protects flies and mice models of AD, PD, HD and ALS No effect on male and harmful in female ALS mice model
Cancer Used therapeutically for renal cell carcinoma Reduces incidence of some cancers
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R750This approach is not as far-fetched as it may first appear.
Drugs often affect more than one disease, metformin and ra-
pamycin being key examples (Table 3). Lifestyle choices
affect multiple diseases: smoking and obesity are risk
factors for most ageing disorders and a good cardiovascular
risk factor profile reduces the overall mortality risk from any
disease [117]. Recent research provides a reason: the same
conserved signalling pathways are involved in most if not all
diseases of old age. These pathways may have been
selected to provide an evolutionary advantage to organisms
in situations of limited resources and exposure to numerous
pathogens, where few individuals reach old age. In labora-
tory animals or western society these conditions no longer
exist, opening the possibility of re-tuning these pathways
to fit new circumstances. Direct manipulation of these path-
ways therefore could offer a more comprehensive, and
possibly cost-effective, way of improving health in later life.
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